New Risk • May 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (€67.2m market cap, or US$78.9m). Announcement • Mar 31
Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026 Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026, at 16:00 W. Europe Standard Time. Location: convendum, fleminggatan 18, stockholm Sweden Board Change • Nov 14
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Aug 13
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • May 07
Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Results on Feb 06, 2026 Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 06, 2026 Announcement • Apr 24
Infant Bacterial Therapeutics to Present Results of the Connection Study at Las 2025 in Hawaii Infant Bacterial Therapeutics (IBT) announced that results from its pivotal Phase III trial, "The Connection Study," will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida. The PAS 2025 Meeting, held from is a premier international forum for pediatric April 24-28, researchers, clinicians, and educators. IBT's presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants. Announcement • Apr 08
Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025 Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: at wetmanska palatset, conference room, bryggarkungen, hollandargatan 17, stockholm Sweden Board Change • Mar 24
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Feb 18
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Jan 11
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Nov 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 30
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 09
Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025 Infant Bacterial Therapeutics AB (publ) announced that the Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board. Board Change • Sep 03
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Aug 31
Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary Endpoints Infant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug candidate IBP-9414, a bacterial strain found naturally in human breast milk, can improve the health of premature infants by preventing necrotizing enterocolitis (NEC) and improve premature infants' gastrointestinal function (measured as time to Sustained Feeding Tolerance, SFT) and, as a secondary objective, reduce death. The results of the study have now been analyzed according to the pre-specified statistical analysis plan. Although these analysis showed positive trends, there were no statistical significance for the two primary endpoints: prevention of necrotizing enterocolitis (NEC), active group: 8.7% vs placebo group: 10.2% (p=0.24) and SFT, active group: 16 days vs placebo group: 17 days (p=0.07). Importantly, there was a significant reduction in the secondary endpoint of all-cause mortality, active group: 6.2% vs placebo group: 8.5% (p=0.04), corresponding to a significant risk reduction of 27%, which meant that in reality 23 infants' lives were spared by the administration of IBP-9414 in the study. IBT will continue the development towards pharmaceutical registration, considering that the study showed statistical significance on all-cause mortality. The previous communicated timeline for the registration might be affected and IBT will revert with an update if any changes will occur. The risk reduction of 27% in mortality is a substantial effect size and comparable to currently available pharmaceutical products, for example, surfactants used in the neonatal intensive care units. The effect of IBP-9414 could potentially save the lives of thousands of infants per year and is the only Live Biopharmaceutical candidate that has shown a strong advantage in saving premature infants' lives. Furthermore the study shows that giving IBP-9414 to these very vulnerable premature infants does not cause any safety issues, including the risk of sepsis which has been a concern expressed by the FDA for the use of probiotic products in preterm infants. Board Change • Aug 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • May 10
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. New Risk • Mar 07
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €91.0m (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 18% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (20% increase in shares outstanding). Market cap is less than US$100m (€91.0m market cap, or US$99.6m). Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 25
Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2024 Infant Bacterial Therapeutics AB (publ) announced the Nomination Committee for the Annual General Meeting 2024 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Per-Erik Andersson (Chairman of the Nomination Committee), appointed by the shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second shareholder, and Jannis Kitsakis, appointed by the third shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board. New Risk • Jul 21
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 19% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 12% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Shareholders have been diluted in the past year (19% increase in shares outstanding). Board Change • Jul 21
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. Independent Director Kristina Nygren was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jan 25
Infant Bacterial Therapeutics AB (publ) Publishes Clinical Findings in British Journal of Gastroenterology Infant Bacterial Therapeutics AB (publ) (IBT) published clinical findings in the British Journal of Gastroenterology on the convincing association of clinical events to the feeding primary endpoint of the Connection Study. The Connection Study on the pharmaceutical grade probiotic IBP-9414 has two independent primary endpoints- the incidence of Necrotizing Enterocolitis (NEC) and the time to a strict definition of Sustained Feeding Tolerance (SFT). SFT is important to reach as early as possible and a critical goal in the neonatal intensive care (NICU) treatment of premature infants. Treatment- blind evaluation of the first 641 infants completing the study with use of quantitative statistics revealed significant delays in the time to reach SFT for 23 examined clinical events characteristic of the NICU treatment of premature infants. The greatest delay occurred in infants with gastrointestinal perforation, hypotension, serious cardiac events and pneumonia (mean delays of 10.1-20.0 days). The time to SFT also strongly influenced the duration of NICU stay and was associated with events like NEC, retinopathy of prematurity, late onset sepsis and days on antibiotics for systemic use. This further builds on the previously published data showing that even a one-day reduction in time to SFT correlates to several clinically meaningful outcomes including reductions in NEC, late onset sepsis, bronchopulmonary dysplasia and antibiotic use. Announcement • Jan 13
Infant Bacterial Therapeutics AB Secures Platform for Pharma Grade Probiotic to Prevent Antibiotic Resistant Hospital Acquired Infections Infant Bacterial Therapeutics AB (IBT) has secured an exclusive global license from the Medical College of Wisconsin (MCW) to a technology platform consisting of genetically modified bacteria. IBT will investigate how to develop a pharma grade probiotic based on this platform that addresses the growing problem of hospital acquired infections, which are responsible for high morbidity and mortality rates. Antibiotic resistance is rising to dangerous levels across the world, including hospital acquired infections caused by vancomycin-resistant enterococci (VRE). VRE infections have become a serious public health challenge linked with the complexities of antibiotic resistance, resulting in 54,000 cases and 5,000 deaths among hospitalized patients in the United States alone. Announcement • Nov 05
Infant Bacterial Therapeutics AB (publ) Announces Nomination Committee Appointments Infant Bacterial Therapeutics AB (publ) announced that the Nomination Committee for the Annual General Meeting 2023 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of Per-Erik Andersson (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board. Announcement • Sep 23
FDA Approves Infant Bacterial Therapeutics' Request for a New Orphan Drug Designation FDA approved Infant Bacterial Therapeutics' request for a New Orphan Drug Designation. Building upon Infant Bacterial Therapeutics AB's (IBT) unique expertise in developing treatment solutions for preterm infants, IBT is at an early stage of investigating the possibilities of developing a drug to prevent retinopathy of prematurity, a growing and serious condition that often leads to blindness among prematurely born babies. The FDA granted orphan drug designation for IBT's product on Sep 20th. Retinopathy of prematurity affects 50-70% of preterm infants weighing less than 1,500 grams at birth, in several cases leading to patients becoming legally blind. Current treatments do not sufficiently address the medical need with severe cases growing significantly from 1.7 to 14.8 per 1,000 preterm infants between the years 1990 and 2011. Orphan drugs are either drugs or biologics intended for the treatment, diagnosis or prevention of rare diseases or disorders affecting less than 200,000 patients in the US per year. An orphan drug designation qualifies the company applying for it to receive certain benefits from the US government, such as tax reductions and long term market exclusivity, in exchange for developing the drug. The approval does not change the standard regulatory requirements and processes for obtaining marketing approval for a product. Consequently, all aspects of the development must be investigated, including the clinical safety and efficacy documentation required for a market authorisation. The drug candidate is a dipeptide developed under the leadership of Dr. Josef Neu, Professor at University of Florida Health, Department of Pediatrics, Division of Neonatology and Dr. Maria Grant, Professor at University of Florida Health, Department of Endocrinology, Diabetes and Metabolism. Announcement • Jul 01
Infant Bacterial Therapeutics AB (publ) Appoints Maria Ekdahl as Chief Financial Officer, Effective September 19, 2022 Infant Bacterial Therapeutics AB (publ) announced that Maria Ekdahl has been appointed Chief Financial Officer (CFO) effective September 19, 2022. She will be part of the Management Team and report to Staffan Strömberg, CEO of IBT. Maria, who has a Master's degree in economics from Linnaeus University, comes to IBT from the Swedish Film Institute where she served as CFO. She brings with her an extensive financial background from organizations including Telenor, Karolinska and Coca-Cola. Announcement • Jan 20
Infant Bacterial Therapeutics Announces the Connection Study Continues After Pre-Scheduled Data Monitoring Committee Review Infant Bacterial Therapeutics announced that the company had reached a key milestone in the development of IBP-9414, after having recruited 600 premature infants to The Connection Study. The Data Monitoring Committee (DMC) has completed its pre-scheduled safety analysis without any concerns. At the same time a futility analysis was performed. Based on DMC recommendations and futility outcome, the company is continuing the recruitment to the study as planned. The phase III study, which started July 2019, is open for recruitment of prematurely born infants between 500g and 1,000g across the US, Bulgaria, France, Hungary, Israel, Poland, Romania, Serbia, Spain, and the UK. Announcement • Jan 11
Infant Bacterial Therapeutics AB Announces New Patent Protection Granted in Australia Infant Bacterial Therapeutics AB announced that the Australian Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBP-9414 is currently in Phase III development for the prevention of necrotizing enterocolitis (NEC) and improvement of feeding tolerance in preterm infants. The ambition for IBP-9414 is to become the world’s first approved pharmaceutical grade probiotic drug to prevent life threatening infant diseases including NEC, by promoting healthy stomach- and bowel development in premature infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are pending in additional important future markets including the US and Europe. This patent further increases the existing protection of IBT’s drug candidate IBP-9414 for which both Orphan Drug Exclusivity and biological data protection have been granted in the USA and EU. The patent provides coverage until 2036. IBP-9414 is intended to be marketed in Australia once market approval has been obtained. Announcement • Dec 28
Infant Bacterial Therapeutics Announces New Patent Protection Approvals in Brazil and in Hong Kong Infant Bacterial Therapeutics AB announced that the Patent Offices of Brazil and Hong Kong have approved a patent of Lactobacillus reuteri covering IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III for the prevention of necrotizing colitis and improvement of feeding tolerance in preterm infants. The patent covers a novel way to activate the bacteria. Corresponding patent applications are currently pending across several important future markets. This patent reinforces the existing protection of IBT’s drug candidate IBP-9414. Additional market protection, beyond patent exclusivity, is also anticipated in the form of Orphan Drug Exclusivity and biological data protection in the US and EU. The patent provides coverage until 2036. IBP-9414 is intended to be marketed in Brazil and Hong Kong upon marketing authorization. Announcement • Sep 25
Infant Bacterial Therapeutics AB (publ) Announces After Safety Review the Connection Study Is Now Again Open to Recruit the Smallest Infants Following the completion of the DMC (Data Monitoring Committee) safety review, Infant Bacterial Therapeutics AB (publ) announced the continuation of the recruitment of patients between 500 - 1000g (Strata A and B) in the Connection study. Given the vulnerability of the Stratum A population, infants with a birth weight less than 750 gram, the company have agreed with the FDA to carefully monitor the safety of these infants. Therefore, the independent DMC has completed an additional safety review,and there are no objections to continue the study. The company expects recruitment to increase as company now again recruit in two strata. Announcement • Sep 11
Infant Bacterial Therapeutics Announces the Mexican Patent Office Grants New Patent Infant Bacterial Therapeutics AB announced that the Mexican Patent Office has granted a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacillus reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase III. The ambition for IBP-9414 is to become approved probiotical drug with the goal to prevent life threatening diseases in premature infants including NEC and sepsis by promoting healthy stomach-and bowel development in premature infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications are currently pending in additional future key markets including the US and Europe. This patent increases the existing protection of IBTs drug candidate IBP-9414 in addition to Orphan Drug Exclusivity and biological data protection already established in the US and EU. The Mexican patent provides coverage until 2036. IBP-9414 is intended to be marketed in Mexico once marketing authorization has been obtained. Announcement • Aug 26
Infant Bacterial Therapeutics AB (Publ) Announces Recruitment of the Smallest Infants in the Connection Study Paused IBT started to recruit infants in Strata A (weight of 500g-749g) in The Connection Study on April 29 2021. Today, 68 infants have been recruited to the group. In accordance with the study protocol and clinical observations, enrolment of infants to Strata A has been paused awaiting a safety review by the Data Monitoring Committee. Subjects already randomized will continue treatment as per protocol, and enrolment of subjects into Strata B (750g-1000g) will continue. IBT is awaiting advice from the DMC before taking any decision regarding further recruitment of infants in Strata A. The DMC is expected to give their opinion in September this year. Recent Insider Transactions • May 11
Director recently bought €37k worth of stock On the 4th of May, Robert Molander bought around 4k shares on-market at roughly €9.36 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €114k more in shares than they have sold in the last 12 months. Announcement • Feb 11
Infant Bacterial Therapeutics Announces That the Recruitment to the First Stage of the Phase III Connection Study Is Completed - an Update About the Clinical Development of IBP-9414 Infant Bacterial Therapeutics (IBT) announced that the company has reached an important milestone after recruiting 300 premature infants to the ongoing clinical Phase III study of IBP-9414. This in part means that a safety analysis of these infants will take place in order to also recruit infants with a very low birth weight, which in turn is expected to significantly increase the recruitment rate. Furthermore it means that IBT has an opportunity to validate the study’s second primary endpoint, feeding tolerance, and redefine this if necessary. IBTs clinical Phase III study of its drug candidate IBP-9414 for the prevention of necrotizing enterocolitis and improvement of feeding tolerance in premature infants, the Connection Study, started in July 2019. There are currently 68 neonatal intensive care units (NICUs) open for recruitment in the study. These NICUs are located in France, Hungary, Israel, Spain, the UK and the USA. The clinical trial application has further recently been approved in Bulgaria and Poland and submitted in Romania and Serbia. IBT expects that approximately 20 NICUs will open for recruitment in the coming months in these newly added countries. The majority of the infants intended to be recruited to the Connection Study will be extremely low birth weight (ELBW) premature infants, i.e they have birth weights of 1000 grams or below. These are the most vulnerable preterm infants and as a precautionary measure the study was designed to include 300 infants with birth weights between 750 and 1000 g in the first stage of the study. After the ongoing safety analysis of these infants the recruitment is intended to be broadened to include infants with a birthweight down to 500 g. This is expected to double the number of infants available for inclusion in the study and company anticipate a significant increase the speed of recruitment in the study. Prior to commencing the Connection Study, IBT agreed with the FDA to perform a pilot analysis of the first 300 patients with the purpose of qualitatively and quantitatively assessing the clinical meaning of the premature infants ability to, as soon as possible, receive enteral feeding without complication. Together with the external neonatology expert group company will analyze the correlation between sustained feeding tolerance and, for example, the incidence of sepsis in the infants. In accordance with the agreement with the FDA, the purpose of the pilot analysis is to validate the second primary endpoint of the study and if necessary redefine it. Through extensive cooperation with the investigating NICUs, IBT has been able to mitigate the pandemics effects on recruitment, and patients have been recruited during the duration of the pandemic. All patients included in the Connection Study are in-hospital patients and therefore no formal outpatient visits are required. Due to this, hospital restrictions on visiting have not affected the Connection Study. Through for example the use of virtual study monitoring, it has also been possible to maintain study quality in relation to patient data capture. The pandemic has however affected recruitment to the study in several ways. Firstly, certain hospitals stopped recruitment to all clinical research studies and new studies were not allowed to start as the relevant research staff were allocated other responsibilities. Further, the staff on duty in the NICUs have in some cases been transferred to COVID-related intensive care departments. In addition, neonatologists in the study as well as scientific journals are reporting a dramatic drop in the numbers of premature infants born into their NICUs during the pandemic. Recruitment rates are expected to significantly increase once the pandemic is under control. Clinical trial supply is functioning well and the IBP-9414 product is well-accepted by hospital pharmacies involved in the Phase III study. IBT is also pleased that the ongoing stability program for the physical product IBP-9414 is going according to plan. Announcement • Feb 10
Infant Bacterial Therapeutics Announces Grant of New Patent in Japan Infant Bacterial Therapeutics AB announced that the Japan Patent Office has issued a decision to grant a patent entitled: A method of activating lactic acid bacteria, which protects the formulation of Lactobacil reuteri including IBP-9414. IBT is currently developing its drug candidate IBP-9414 in Phase I I for the prevention of NEC and improvement of feeding tolerance in preterm infants. The invention covers a novel way to activate the freeze-dried bacteria and corresponding patent applications for the invention are currently pending in additional important future markets including the US and Europe. This patent further increases the existing protection of IBTs drug candidate IBP-9414 for which both Orphan Drug Exclusivity and biological data protection have been granted in the USA and EU. The Japanese patent expires in 2036 and the IBP-9414 product covered by this patent is intended to be marketed in Japan after future marketing authorization. Is New 90 Day High Low • Jan 07
New 90-day low: €10.30 The company is down 38% from its price of €16.56 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 10.0% over the same period. Is New 90 Day High Low • Dec 22
New 90-day low: €10.64 The company is down 39% from its price of €17.36 on 22 September 2020. The German market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Dec 04
New 90-day low: €11.94 The company is down 31% from its price of €17.38 on 04 September 2020. The German market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 3.0% over the same period. Is New 90 Day High Low • Nov 18
New 90-day low: €12.02 The company is down 27% from its price of €16.52 on 20 August 2020. The German market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. 